BioDelivery Sciences (BDSI) Anticipates $15M Private Placement, Holds Conference Call to Discuss Key Items

QualityStocks would like to highlight BioDelivery Sciences International (NASDAQ: BDSI), a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. The company is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.

In the company’s news yesterday,

BioDelivery Sciences International has announced it has received definitive commitments from institutional investors for a private placement financing with gross proceeds totaling $15 million.

Per the securities purchase agreement, BioDelivery will sell an aggregate 4,807,693 shares of its common stock at a purchase price of $3.12 per share, a 10 percent discount to an agreed-upon volume-weighted average price of the company’s stocks.

BioDelivery has allotted the financing toward the progression of the clinical development of its product pipeline, with a focus on BEMA Buprenorphine and BEMA Buprenorphine/Naloxone. Proceeds are expected to strengthen the company’s balance sheet as it works through partnering negotiations for BEMA Buprenorphine.

The company also announced it has filed its Annual Report with the SEC on Form 10-K for the fiscal year ended December 31, 2010, available on the SEC’s Web site at www.sec.gov.

BioDelivery held a conference call to discuss the financing components of the company’s 10-K; an update on its product pipeline; commercial outlook for Onsolis, the company’s approved product for the management of pain in adults with cancer; and anticipated milestones for 2011.

A replay of the conference call is available on BioDelivery’s Web site, www.bdsi.com

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.